Business
Check-Cap Announces Grant of Patent Covering C-Scan's Proprietary Tracking Technology in the U.S. and Additional Major Market Territories
Patent valid through May 2034 ISFIYA, Israel, Nov. 2, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a
About this update from Check-cap Ltd.
[{"type":"text","content":"Patent valid through May 2034\n\n\nISFIYA, Israel, Nov. 2, 2021 /PRNewswire/ -- Check-Cap Ltd. (the \"Company\" or \"Check-Cap\") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the United States Patent and Trademark Office (USPTO), has issued a decision to grant a patent covering C-Scan's proprietary tracking technology. \nThis new, patent titled \"Position Estimation of Imaging Capsule in Gastrointestinal Tract\", claims the proprietary tracking technology developed at Check-Cap that allows the C-Scan® system to accurately track the C-Scan capsule within the patient's body and enables real time activation of the capsule when the capsule moves throughout the colon. This functionality comprises the benefits of optimal scanning along the GI tract while maintaining low energy consumption during the procedure. The patent also covers capsule positioning data recording for the C-Scan analysis suite, which enables gastroenterologists to make a clinical decision and generate a report with their diagnosis and recommendations. This patent will expire in May 2034, subject to appropriate maintenance and renewal. Corresponding patents issued in Japan and China and patents approved for granting in Europe and Israel.\n\"This strategic patent further protects the global rights of our technology,\" said Alex Ovadia, Check-Cap's chief executive officer. \"The development of a solution that ensures powering optimization and tracking of an ingestible capsule throughout the whole scanning procedure is key, and we believe that this patent further positions our disruptive technology as one of the most advanced of its kind worldwide. Furthermore, this technology opens potential opportunities for additional applications such as localized drug delivery. With more than 50 granted patents worldwide, covering key strategic aspects of our deep tech foundations, we continue our commitment to enhance and protect the rights over our unique technology that is designed to offer the many people in need, a patient-friendly advanced option for the detection of precancerous polyps.\"\nAbout Check-Cap \nCheck-Cap is a clinical stage medical ...